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BACKGROUND: Trastuzumab has recently shown efficacy in the treatment of HER2-positive advanced gastric adenocarcinoma.
Although antibody-based therapies target the metastatic disease, HER2 status is usually evaluated in the primary tumour because
metastatic sites are rarely biopsied. The aim of this study was to compare HER2 status in primary and paired metastatic sites of gastric
adenocarcinoma.
METHODS: The HER2 status was assessed by fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) in 72
secondary lesions of gastric adenocarcinoma and in the corresponding primary tumours.
RESULTS: Concordance of FISH results, evaluable in 68 primary and matched metastatic sites, was 98.5%. Concordance of IHC results,
available in 39 of the 72 paired cases, was 94.9%. Only one case showed discordance between primary tumour and metastasis, being
negative by both IHC and FISH in the primary and showing HER2 overexpression and amplification in the corresponding pancreatic
lymph node metastasis.
CONCLUSION: The high concordance observed between HER2 results obtained by both IHC and FISH on primary tumours and
corresponding metastases suggests that in gastric cancer HER2 status is maintained in most cases unchanged during the metastatic
process.
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Trastuzumab in combination with chemotherapy can be consid-
ered as a new standard option for patients with HER2-positive
advanced gastric or gastroesophageal junction cancer (Bang et al,
2010). In gastric adenocarcinoma, HER2 gene amplification or
protein overexpression is found in 7–34% of primary tumours
(Takehana et al, 2002; Tanner et al, 2005; Park et al, 2006; Gravalos
and Jimeno, 2008; Hofmann et al, 2008; Barros-Silva et al, 2009;
Marx et al, 2009). Although trastuzumab-based therapy is used to
treat metastatic disease, HER2 status is generally evaluated in the
primary lesions because metastatic sites are rarely removed or
biopsied before treatment. However, it is still unknown whether
HER2 status differs in metastases compared with primary
tumours. To date, only one study has addressed this issue showing
a high level of concordance between HER2 status evaluated on
primary tumours and regional lymph node metastases by means of
both immunohistochemistry (IHC) and fluorescence in situ
hybridisation (FISH; Marx et al, 2009).
In this study, HER2 status was assessed by FISH and IHC on
samples obtained from metastatic sites of gastric carcinomas and
paired primary tumours. The aim of the study was establishing
whether HER2 status assessed on primaries could be reliable for
treatment decisions with anti-HER2 agents in patients with
metastatic gastric cancer.
MATERIALS AND METHODS
The current series included 72 consecutive patients with gastric
adenocarcinoma who underwent diagnostic fine-needle aspiration
biopsy (FNAB) or tissue biopsy or surgical resection of
synchronous or metachronous metastatic lesions. Tissue speci-
mens of the paired primary tumours (18 endoscopic biopsies and
54 gastric resections) were available for all patients. The HER2
status was tested by FISH in both cytological and histological
samples. The HER2 FISH results were confirmed by IHC on
available histological sections. None of the patients were treated
with trastuzumab-based regimens.
Cytological specimens
Cytological smears from metastatic lesions were obtained by
multidirectional ultrasound-guided FNAB using a 22-gauge for
deep lesion and 22–23 gauge for superficial lesions. The aspirated
material was smeared on glass slides and air dried. Cellular
suspensions obtained from pleural and ascitic fluids were
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scytocentrifuged and air dried. At least two slides were stained with
May–Gru ¨nwald–Giemsa for routine cytology. The remaining
slides were kept unstained at  201C until assay. After cytological
diagnosis of malignancy, one representative slide was submitted to
HER2 FISH.
Histological specimens
Formalin-fixed, paraffin-embedded tissue blocks, selected on the
basis of quality and representativeness of the sample, were cut into
3-mm thick sections that were submitted to both FISH and IHC.
For each case, two tissue sections cut at different levels of
the histological block were processed to control for tissue
heterogeneity.
HER2 assessment – FISH
The HER2 amplification was assessed on both histological and
cytological samples using a Spectrum Green fluorophore-labeled
a-satellite DNA probe for chromosome 17 (Chr17) and a Spectrum
Orange fluorophore-labeled DNA probe for the HER2 gene
locus (Vysis PathVysion HER-2 DNA Probe Kit, Vysis-Abbott,
Wiesbaden, Germany). Slides were hybridised using a Hybrite
denaturation/hybridisation system for FISH (Vysis). Details of the
method were previously described (Bozzetti et al, 2003). The FISH
images were processed utilising an Olympus MX60 fluorescence
microscope (Olympus, Hamburg, Germany) with a 100-W mercury
lamp. Separate narrow band pass filters were used for the detection
of spectrum orange, spectrum green and DAPI. At least 100
evaluable nuclei for each case were scored visually in different
tumour areas by two independent observers in blind (CB, CL)
giving superimposable results. Cases showing two Chr17 in 450%
of cells were classified as disomic. Chromosome 17 polysomy was
defined as X3 CEP17 signals on average per cell. Amplification
was defined as a HER2/CEP17 ratio X2, or when an HER2 signal
cluster was observed (Hofmann et al, 2008).
HER2 assessment – IHC
Sections of archival formalin-fixed, paraffin-embedded tissue
(3mm) were placed on slides coated with poly-L-lysine. After
deparaffinisation and blocking of endogenous peroxidase, HER2
immunostaining was performed using rabbit anti-human
c-erbB-2 oncoprotein as primary antibody (Dako Corp, Carpinteria,
CA, USA) at 1/100 dilution. Binding of the primary antibody was
revealed by means of the Dako Quick-Staining, Labelled Strepta-
vidin–Biotin System (Dako), followed by the addition of
diaminobenzidine as a chromogen.
The HER2 immunoreactivity was evaluated by an experienced
pathologist according to the scoring system of Hofmann et al
(2008). Resection samples exibiting a strong (3þ) complete,
basolateral or lateral membranous reactivity in X10% of the cells
were scored as positive. Samples with no reactivity or membranous
reactivity in o10% or faint or barely perceptible membranous
reactivity (1þ)i nX10% of tumour cells (cells are reactive only in
part of their membrane) were considered negative. Samples
showing a weak to moderate complete, basolateral or lateral
membranous reactivity (2þ)o fX10% of tumour cells were
scored as equivocal. For tumour biopsy specimens the same
patterns were considered, but irrespective of the percentage of
tumour cells.
Statistics
Pearson’s correlation test was used to compare the HER2 status
assessed by IHC and FISH on metastatic sites. A strong correlation
was defined as a correlation coefficient rX0.8.
Concordance between IHC status on primary vs metastatic sites
was calculated as the ratio of concordant cases to total cases. The
k-coefficient was used to assess the level of agreement between
samples. The k-values ranging from 0.61 to 0.8 were assumed to
indicate a very good agreement; Po0.05 allowed us to reject the
null hypothesis that there is no agreement.
Differences were considered statistically significant when the
P-value was p0.05. All statistical tests were two-sided.
RESULTS
The HER2 gene copy number was evaluated by FISH in 72
consecutive primary gastric adenocarcinomas (18 biopsies and 54
resection specimens) and their corresponding metastatic lesions
(33 FNAB samples, 9 core tissue biopsies and 30 surgical
resections). The main characteristics of the patients are sum-
marised in Table 1. Secondary lesions were localised to liver
(n¼19), pleura (n¼4), peritoneum (n¼19), skin (n¼4), regional
lymph nodes (n¼2), distant lymph node (n¼14) and 10 to other
sites. Of the 33 metastatic lesions sampled by cytology, 79% (26/33)
were metachronous compared with 26% (10/39) of those sampled
by surgery. In all, 4 of the 72 primary tumour specimens were not
suitable for HER2 status assessment because of the poor fixation of
tissue, whereas all specimens from metastatic sites were adequate
for evaluation.
Among the metastatic lesions, HER2 amplification was observed
in 3 of the 33 (9%) cytological and 8 of the 39 (21%) histological
specimens. In total, HER2 amplification was present in 11 of the 72
(15%) metastases. Two of the three HER2-amplified cytological
samples (one retroperitoneal lymph node and one liver metastasis)
showed a HER2 cluster pattern in the whole-tumour cell
Table 1 Patient characteristics
No. of patients (n¼72) %
Gender
Male 50 69
Female 22 31
Age, range 49–88
Type of intervention
Surgical resection 58 81
Biopsy 14 19
Primary tumour site
Gastroesophageal junction 6 8
Other 66 92
Histology
Lauren classification
Diffuse 29 40
Intestinal 33 46
Mixed 6 8
Not classified 4 6
Metastatic sites
Liver 19 26
Pleural fluid 4 6
Ascitic fluid 11 15
Skin 4 6
Lymph nodes
Regional 2 3
Distant 14 19
Peritoneum 8 11
Other sites 10 14
Synchronous metastases 36 50
Metachronous metastases 36 50
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spopulation, whereas the third sample, a sovraclavear lymph node
metastasis, had an average gene copy number of 12 and a HER2/
CEP17 FISH ratio of 4.0 in 90% of tumour cells. All three amplified
metastatic lesions sampled by cytology were synchronous.
A cluster pattern of amplification was present in the eight HER2-
positive metastases sampled by core tissue biopsy (seven liver and
one pancreatic lesions); seven of these were synchronous and one
metachronous.
Of the 61 HER2-negative metastases, 28 (46%) were disomic
and 33 (54%) polysomic. No difference was observed in the
distribution of HER2 gene copy number, between FNAB samples
(n¼26; mean value¼3.29) and core biopsy or surgical resection
samples (n¼31; mean value¼2.96) (independent samples
t-test¼NS).
The HER2 amplification was observed in 10 of the 68 (15%)
primary tumours (Table 2). Among them, nine cases showed a
cluster amplification in 490% of tumour cells population, whereas
one case showed intra-tumour heterogeneity, having a different
HER2 asset in different areas of the tumour: 33% of tumour cells
had an average HER2 gene copy number of 4.5 and a HER2/CEP17
ratio of 2.4, whereas polysomy was present in 67% of nuclei with
an average HER2 gene copy number of 3.6 and a HER2/CEP17
FISH ratio of 1.27. In all, 34 (59%) of the 58 unamplified primary
tumours were disomic, and 24 (41%) polysomic. A r
2 of 0.937 and
of 0.962 was found for FISH count by two independent observers
in primary and metastatic lesions, respectively.
Among the 68 cases assayed by FISH on both primary and
paired metastatic site, 10 cases were amplified in both specimens
(Table 2). In all, 9 of the 10 cases showed a cluster amplification in
both primary and metastasis; the tumour with heterogeneous
HER2 amplification in the primary showed an increase in both
HER2 gene copy number (4.5 vs 12.0) and the percentage of
amplified cells (33 vs 90%) in the matched metastasis. A single case
showed primary vs metastasis discordance, being unamplified in
the primary tumour (Figure 1A) and exhibiting a cluster
amplification in 20% of tumour cells in the matched synchronous
pancreatic lymph node biopsy (Figure 2A).
The HER2 protein overexpression was assessed by IHC on
histological sections obtained from the 72 primary tumours and
the 39 metastatic lesions sampled by core biopsies or surgical
resection. In all, 10% (7/68) of the cases resulted positive by IHC, 6
of them showing a immunopositive (3þ) reaction in 480% of
tumour cells and 1 in 50% of tumour cells. The total concordance
between IHC and FISH was 95.6%. FISH and IHC results in the 68
comparable primary tumours are shown in Table 3.
As to the 39 metastasis specimens assessed by IHC, 22 cases
were negative by both IHC and FISH, 7 were positive by both
techniques and 10 cases were ICH equivocal, 9 of which resulted
FISH negative (Table 4). Table 5 shows the comparison between
HER2 protein expression evaluated on histological sections of 39
Table 2 HER2 FISH on distant metastatic sites of gastric carcinoma and
matched histological specimens from the primary tumours
HER2 distant metastatic sites
FISH  FISH+
HER2 primary tumours
FISH  57 1
FISH+ 0 10
Abbreviations: FISH¼fluorescence in situ hybridisation; HER2¼human epidermal
growth factor receptor 2. n¼68. Concordance¼98.5%.
Figure 1 Gastric carcinoma with neither HER2 amplification (A) nor protein overexpression (B) in the primary tumour. Original magnification:
(A)  1250; (B)  400.
Figure 2 The HER2 cluster amplification (A) and protein overexpression (B) in the lymph node metastasis of the primary gastric carcinoma shown in
Figure 1. Original magnification: (A)  1250; (B)  400.
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sprimary tumours and paired metastatic sites. Overall concordance
was 94.9%. Of the 39 matched cases the single discordant case was
that also showing discordant FISH results. In this case, HER2
immunostaining was negative in the primary tumour (Figure 1B),
whereas it showed a strong basolateral staining in 15% of cells in
the metastasis (Figure 2B).
DISCUSSION
The HER2 status in gastric carcinoma can be evaluated by IHC or
FISH technique and is usually assessed on the primary tumour
because patients with recurrent disease rarely undergo surgery or
biopsy. The issue of concordance of HER2 status between primary
tumour and metastasis has been scarcely addressed in the
scientific literature. Only one study (Marx et al, 2009) has been
previously published on this subject. The authors reported an
identical HER2 status, as assessed by FISH, in 49 primary tumours
and their corresponding lymph node metastases.
Our results confirmed a high level of concordance between IHC
and FISH methodologies to assess HER2 status in gastric cancer, as
previously reported by other authors (Takehana et al, 2002; Yano
et al, 2006; Hofmann et al, 2008; Marx et al, 2009).
The high concordance observed between IHC and FISH results
on primaries and corresponding metastases, points out that in
gastric cancer HER2 status is maintained in most cases unchanged
during the metastatic process. However, given the low number of
cases analysed, at the present time we cannot draw any conclusion
about HER2 asset in synchronous and metachronous metastases.
The HER2 amplification was observed in 21% of the metastatic
lesions sampled by histology and in 9% of those sampled by
cytology. This difference cannot be ascribed to a bias of cytology
given that FISH results were entirely concordant with those
obtained on the histological specimens of the corresponding
primary tumours. It is likely that the discrepancy observed
between the rate of cases scored as positive on cytology and on
histology could depend on the small sample size deserving further
validation in a larger cohort of patients. However, among
cytological cases, one tumour HER2 amplified on both the primary
and the metastasis, was discordant by IHC.
The HER2 amplification status was evaluable by FISH in 68
paired primary and metastatic lesions: 10 were amplified and 57
unamplified in both sites. Only one discordant case was found,
being unamplified in the primary tumour and showing a cluster
amplification in 20% of tumour cells in the matched pancreatic
lymph node metastasis. This result was confirmed by IHC. Among
cases amplified in both the primary and the metastatic lesion, one
primary tumour showed the coexistence of clones with a low level
of HER2 amplification in the context of a prevalent polysomic cell
population. The percentage of amplified cells increased from 33 to
90% in the paired metastasis sampled by cytology, with a gain in
both HER2 gene copy number (12.0 vs 4.5) and HER2/CEP17 FISH
ratio (4.0 vs 2.4). The case was also HER2 negative by IHC on the
primary; unfortunately, HER2 expression was not evaluable on the
metastasis that was sampled by cytology.
The FISH is considered negative for HER2 amplification if gene
copy number is o4 and equivocal when the number is 4.0 to 6.0
following the American Society of Clinical Oncology/College of
American Pathologist guideline recommendations (Shah et al,
2010). On the basis of these criteria that were elaborated in breast
cancer, the latter case should be considered discrepant as HER2
was equivocal in the primary tumour, whereas amplification was
found in the metastasis. As intratumoural heterogeneity of HER2
amplification is more common in the stomach than in the breast
(Hofmann et al, 2008), validation of current criteria might be
warranted for gastric cancer. The case also suggests potential
mechanisms to explain discrepancy. In fact, at least part of the
discrepant cases might arise by a clonal selection of HER2-positive
cells over disease progression. The higher mean of HER2 gene copy
number observed in cytological samples of metastases compared
with primary tumours is also better explained by enrichment of
HER2-positive cells from a starting heterogeneous tissue rather
than by technical issues such as sampling or FISH evaluation of
intact vs truncated nuclei.
As concerns the other cases defined as positive by FISH, we
observed that amplification was present within the whole-tumour
cell population; on the other hand a immunopositive reaction
(3þ) was present at least in 50% of tumour cells in all the cases
scored as positive by IHC.
Another question, still matter of debate in breast cancer,
concerns the clinical significance of Chr17 polysomy on survival
and response to trastuzumab therapy (Rosenberg, 2008). Com-
pared with breast cancer in which o10% of tumours shows
Table 3 HER2 status assessed by FISH and IHC in 68 primary gastric
carcinomas
IHC score
Negative
Equivocal Positive
0 1+ (2+) (3+)
FISH+ 1 0 2 7
FISH  44 7 7
Total 45 7 9 7
Abbreviations: FISH¼fluorescence in situ hybridisation; HER2¼human epidermal
growth factor receptor 2; IHC¼immunohistochemistry. Concordance: 95.6%.
Table 4 Comparison of HER2 status assessed by both IHC and FISH on
39 histological sections obtained from metastatic sites of gastric carcinoma
FISH
Negative, n (%) Positive, n (%)
IHC score
Negative
01 2
1+ 10
Equivocal (2+) 9 1
Positive (3+) 7
Abbreviations: FISH¼fluorescence in situ hybridisation; HER2¼human epidermal
growth factor receptor 2; IHC¼immunohistochemistry. n¼39. Pearsons’s
R¼0.829, Po0.001.
Table 5 Comparison of HER2 status assessed by IHC on 39 primary
gastric carcinomas and corresponding metastatic sites
IHC metastatic sites
Negative
Equivocal (2+) Positive (3+)
01 +
IHC primary tumours
Negative
01 2 3 2 1
1+ 6 1
Equivocal (2+) 1 7 1
Positive (3+) 5
Abbreviations: HER2¼human epidermal growth factor receptor 2; IHC¼immuno-
histochemistry. n¼39. k¼0.723, Po0.001.
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sincreased CEP17 copy number (Shah et al, 2010), we observed a
prevalence of 35.3% (24/68) of Chr17 polysomy in our series, an
observation that underscores the need of further investigations on
the predictive and prognostic significance of Chr17 polysomy in
gastric carcinoma.
The results of the phase III ToGA trial (Bang et al, 2010) indicate
trastuzumab plus cisplatin and fluoropyrimidine chemotherapy as
the standard of care for patients with HER2-positive advanced
gastric cancers. In this setting, the present findings are clinically
relevant as they confirm current clinical practices in the
assessment of HER2 status. Nonetheless, the evidence of two
HER2-positive metastasic lesions with one negative and one
equivocal primaries suggest that HER2 reassessment of the
metastasis might be considered in selected cases when this would
change the therapeutic decision.
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